TMDX Stock Forecast & Price Target

TransMedics Group is viewed favorably because its OCS platform addresses a large unmet need by improving organ utilization and outcomes versus cold storage, with an estimated nearly $8B market across lung, heart, and liver and a differentiated, FDA-approved multi-organ platform. The company’s 2025 sales of $605 million, up 37% from 2024, show strong commercial traction, while 3Q26 data, May flight growth of +20% and June-to-date growth above +30% suggest a rebound in transplant activity and continued share gains. Fundamentally, the bullish case rests on a 2027 inflection as ENHANCE Part B, DENOVO, CHOPS, OCS Kidney, Italy, and aviation scale into the revenue base, supporting operating leverage despite ongoing investment.

TransMedics Group is viewed negatively because its growth depends on a narrow OCS platform facing regulatory, reimbursement, and competitive risk, while clinical delays in 2026 forced higher spending without the expected revenue contribution. Operating trends also look less resilient: 1Q26 showed roughly $83M of adjusted opex, about $3.8M of lease-related interest in the quarter, and the analyst raised annual interest expense to $28.8M, cutting FY26 and FY27 adj. EPS to $1.86 and $3.05. Margin pressure in Service and Product, plus potential share loss to OrganOx and uncertain durability of recent transplant volume growth, suggest core fundamentals may not support a premium valuation.